Theriva Historical Cash Flow
| TOVX Stock | USD 1.47 0.15 9.26% |
Analysis of Theriva Biologics cash flow over time is an excellent tool to project Theriva Biologics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Total Cash From Financing Activities of 682.8 K or End Period Cash Flow of 28.1 M as it is a great indicator of Theriva Biologics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Theriva Biologics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Theriva Biologics is a good buy for the upcoming year.
Theriva |
About Theriva Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Theriva balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Theriva's non-liquid assets can be easily converted into cash.
Theriva Biologics Cash Flow Chart
Add Fundamental
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Theriva Biologics financial statement analysis. It represents the amount of money remaining after all of Theriva Biologics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Total Cashflows From Investing Activities
The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.Most accounts from Theriva Biologics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Theriva Biologics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theriva Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.At this time, Theriva Biologics' Change In Working Capital is fairly stable compared to the past year. Begin Period Cash Flow is likely to rise to about 50.6 M in 2025, despite the fact that Change In Cash is likely to grow to (20.3 M).
Theriva Biologics cash flow statement Correlations
Click cells to compare fundamentals
Theriva Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Theriva Biologics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (8.8M) | 61.1M | (25.4M) | (18.6M) | (21.4M) | (20.3M) | |
| Free Cash Flow | (13.9M) | (12.2M) | (12.9M) | (19.2M) | (17.3M) | (18.1M) | |
| Change In Working Capital | (2.8M) | 875K | (806K) | 2.3M | 2.1M | 2.2M | |
| Begin Period Cash Flow | 15.0M | 6.2M | 67.3M | 41.9M | 48.2M | 50.6M | |
| Other Cashflows From Financing Activities | (9K) | 8.0M | (266K) | (1.5M) | (1.4M) | (1.3M) | |
| Other Non Cash Items | 178K | 952K | 2.3M | (2.0M) | (1.8M) | (1.7M) | |
| Total Cash From Operating Activities | (12.2M) | (12.9M) | (19.1M) | (19.0M) | (17.1M) | (18.0M) | |
| Net Income | (10.1M) | (14.3M) | (19.7M) | (18.3M) | (16.5M) | (17.3M) | |
| End Period Cash Flow | 6.2M | 67.3M | 41.9M | 23.3M | 26.8M | 28.1M | |
| Stock Based Compensation | 350K | 416K | 475K | 552K | 496.8K | 472.0K | |
| Investments | (9K) | (14K) | (4.4M) | (237K) | (213.3K) | (224.0K) | |
| Change To Operating Activities | (427K) | (1.4M) | 1.2M | (238K) | (273.7K) | (287.4K) | |
| Issuance Of Capital Stock | 3.4M | 66.0M | 2.7M | 2.2M | 1.9M | 1.8M | |
| Change To Netincome | 335K | 455K | 415K | 1.1M | 1.3M | 1.4M | |
| Change To Liabilities | 1.3M | (1.4M) | (363K) | (385K) | (346.5K) | (363.8K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.